Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell malignancy requiring prompt systemic treatment. For newly diagnosed patients, the initial therapeutic strategy is administered with curative intent.
The standard first-line regimen is anthracycline-based chemoimmunotherapy, given with curative intent. The complete drug combination, cycle count, and clinical decision algorithm are detailed in the full protocol.
For decades, chemoimmunotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) has been the standard initial DLBCL treatment.
For patients with advanced-stage disease, those with low-risk DLBCL (IPI 0-1) and those with the GCB subtype have very good outcomes when treated with 6 cycles of standard R-CHOP treatment.